TRPC3
Short transient receptor potential channel 3
Also known as: TRPC3_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q13507
- Gene
- TRPC3
- Ensembl
- ENSG00000138741
- Chromosome
- 4
- Canonical length
- 921 aa
- Protein class
- Disease related genes, Human disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels
- Quaternary structure
- Homotetramer
OverviewNCBI Gene
The protein encoded by this gene is a membrane protein that can form a non-selective channel permeable to calcium and other cations. The encoded protein appears to be induced to form channels by a receptor tyrosine kinase-activated phosphatidylinositol second messenger system and also by depletion of intracellular calcium stores. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Oct 2011]
Canonical amino-acid sequenceUniProt
921 residues, UniProt reviewed canonical sequence.
>Q13507|TRPC3
1 MSTKVRKCKE QARVTFPAPE EEEDEGEDEG AEPQRRRRGW RGVNGGLEPR SAPSQREPHG
61 YCPPPFSHGP DLSMEGSPSL RRMTVMREKG RRQAVRGPAF MFNDRGTSLT AEEERFLDAA
121 EYGNIPVVRK MLEESKTLNV NCVDYMGQNA LQLAVGNEHL EVTELLLKKE NLARIGDALL
181 LAISKGYVRI VEAILNHPGF AASKRLTLSP CEQELQDDDF YAYDEDGTRF SPDITPIILA
241 AHCQKYEVVH MLLMKGARIE RPHDYFCKCG DCMEKQRHDS FSHSRSRINA YKGLASPAYL
301 SLSSEDPVLT ALELSNELAK LANIEKEFKN DYRKLSMQCK DFVVGVLDLC RDSEEVEAIL
361 NGDLESAEPL EVHRHKASLS RVKLAIKYEV KKFVAHPNCQ QQLLTIWYEN LSGLREQTIA
421 IKCLVVLVVA LGLPFLAIGY WIAPCSRLGK ILRSPFMKFV AHAASFIIFL GLLVFNASDR
481 FEGITTLPNI TVTDYPKQIF RVKTTQFTWT EMLIMVWVLG MMWSECKELW LEGPREYILQ
541 LWNVLDFGML SIFIAAFTAR FLAFLQATKA QQYVDSYVQE SDLSEVTLPP EIQYFTYARD
601 KWLPSDPQII SEGLYAIAVV LSFSRIAYIL PANESFGPLQ ISLGRTVKDI FKFMVLFIMV
661 FFAFMIGMFI LYSYYLGAKV NAAFTTVEES FKTLFWSIFG LSEVTSVVLK YDHKFIENIG
721 YVLYGIYNVT MVVVLLNMLI AMINSSYQEI EDDSDVEWKF ARSKLWLSYF DDGKTLPPPF
781 SLVPSPKSFV YFIMRIVNFP KCRRRRLQKD IEMGMGNSKS RLNLFTQSNS RVFESHSFNS
841 ILNQPTRYQQ IMKRLIKRYV LKAQVDKEND EVNEGELKEI KQDISSLRYE LLEDKSQATE
901 ELAILIHKLS EKLNPSMLRC ELocalizationUniProt · AlphaFold · HPA
Whether an antibody against TRPC3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 6
- Mean surface accessibility (rSASA)
- 0.37
- Highest tissue expression
- 7 nTPM
Expression across tissuesHPA
Tissue
- pituitary gland: 7 nTPM
- basal ganglia: 4.7 nTPM
- retina: 3.6 nTPM
- cerebellum: 2.9 nTPM
- smooth muscle: 2.5 nTPM
- urinary bladder: 1.7 nTPM
Single-cell type
- other brain neurons: 224 nCPM
- lactotrophs: 197 nCPM
- thyrotrophs: 109 nCPM
- retinal ganglion cells: 97 nCPM
- rod photoreceptor cells: 83 nCPM
- pericytes: 63 nCPM
Immune cell
- basophil: 0.2 nTPM
- MAIT T-cell: 0.2 nTPM
- neutrophil: 0.1 nTPM
- non-classical monocyte: 0.1 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
Brain region
- medulla oblongata: 25 nTPM
- cerebral cortex: 19 nTPM
- thalamus: 12 nTPM
- cerebellum: 12 nTPM
- basal ganglia: 11 nTPM
- hypothalamus: 9.1 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about TRPC3.
Disease | AllUniProt
Conditions TRPC3 is implicated in, by any mechanism.
- Spinocerebellar ataxia 41 (SCA41) MIM:616410
Disease | GeneticClinVar
1 pathogenic / likely-pathogenic of 224 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Spinocerebellar ataxia type 41
ReferencesPubMed · IEDB
Publications for TRPC3 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
2 publications
- Autoantibodies against TRPC3 and ryanodine receptor in myasthenia gravis.
2008 · J Neuroimmunol · RCR 0.4 · 18 citations - [Recent advance in research for myasthenia gravis, in relation to various antibodies affecting synaptic structure and function].
2009 · Rinsho Shinkeigaku
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.7
- gnomAD pLI
- 0
- gnomAD missense Z
- 3.84
- DepMap mean gene effect
- 0.02
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- calcium ion transmembrane transport
- calcium ion transport
- phototransduction
- positive regulation of calcium ion transport into cytosol
- positive regulation of cardiac muscle hypertrophy in response to stress
- regulation of cytosolic calcium ion concentration
- response to ATP
- response to calcium ion
- single fertilization
Molecular functions
- calcium channel activity
- calcium-activated cation channel activity
- inositol 1,4,5 trisphosphate binding
- metal ion binding
- store-operated calcium channel activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of TRPC3 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads TRPC3 as an antibody target. Whether an autoantibody or antibody against TRPC3 could matter depends on whether native TRPC3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
TRPC3 is annotated at the cell surface, where native TRPC3 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label TRPC3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...